查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1589210

重症加護治療市場：按藥物類別、按應用分類 - 2025-2030 年全球預測

Critical Care Therapeutics Market by Drug Class (Albumin, Antithrombin Concentrates, Factor XIII Concentrates), Application (Acute Coronary Syndrome, Atrial Fibrillation, Coronary Angioplasty) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年重症加護治療市場價值為47.7億美元，預計到2024年將達到50.3億美元，複合年成長率為5.39%，到2030年將達到69億美元。

重症加護治療包括廣泛的醫療解決方案，專注於治療需要密集監測和支持的危及生命的病症，例如嚴重感染疾病、器官衰竭和嚴重的術後病症。由於慢性病的流行、人口老化以及需要專門護理的嚴重健康狀況的發生率不斷增加，因此需要此類治療劑。應用涵蓋各種醫療保健環境，包括醫院和專用加護病房(ICU)，最終用途為成人和兒科醫學。市場開拓的主要驅動力是生物技術和製藥的進步，這導致了標靶治療和個人化醫療解決方案的發展。此外，人工智慧診斷和遠距加護病房等數位健康技術代表了市場擴張的廣泛機會。醫療保健專業人員和醫療機構可以利用這些技術來改善患者的治療效果和業務效率。然而，由於高昂的治療成本、嚴格的監管要求以及與先進治療相關的潛在副作用，該市場面臨限制。此外，COVID-19 大流行暴露了醫療基礎設施的脆弱性，並對重症監護服務的適應性和資源分配提出了挑戰。為了充分利用成長機會，相關人員應專注於生物相似藥和單株抗體創新，這些創新有望提供更具成本效益的治療方法。此外，對穿戴式健康監測技術的投資和巨量資料分析的整合可以為患者管理和護理途徑最佳化提供見解。市場本質上是動態和競爭的，需要不斷創新並適應不斷變化的醫療保健環境。公司應優先考慮合作研究舉措並加強跨部門夥伴關係以推動成長。專注於對醫療保健專業人員進行最新療法和技術的教育和培訓將進一步推動重症加護治療領域的市場滲透和永續性成功。

主要市場統計
基準年[2023] 47.7億美元
預測年份 [2024] 50.3億美元
預測年份 [2030] 69億美元
複合年成長率（%） 5.39%

市場動態：快速發展的重症加護治療市場的關鍵市場洞察

供應和需求的動態交互作用正在改變重症加護治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球老年人口不斷增加，慢性病盛行率不斷上升
    • 數位化趨勢和久坐生活方式引起的疾病
    • 對醫療保健產業現代治療設施的重大投資
  • 市場限制因素
    • 治療藥物高成本
  • 市場機會
    • 政府對引進重症加護診斷的活動和支持
    • 增加診斷和實驗室之間的遠端通訊
  • 市場挑戰
    • 缺乏熟練的專業人員

波特的五力：駕馭重症加護治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解重症加護治療市場的外部影響

外部宏觀環境因素在塑造重症加護治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解重症加護藥物市場的競爭格局

對重症加護治療市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV重症加護治療市場中的定位矩陣供應商績效評估

FPNV 定位矩陣是評估重症加護治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了重症加護治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對重症加護治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地的老年人口不斷增加，慢性病的盛行率也增加。
      • 數位化趨勢和久坐生活方式引起的疾病
      • 現代醫療設施在醫療保健領域的重大投資
    • 抑制因素
      • 治療費用上漲
    • 機會
      • 政府對實施加護治療診斷的活動和支持
      • 增加診斷和實驗室之間的遠端通訊
    • 任務
      • 缺乏熟練的專業人員
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的重症加護治療藥物市場

  • 白蛋白
  • 抗凝血酵素濃縮物
  • 因子 XIII 濃縮物
  • 纖維蛋白原濃縮物
  • 凝血酶原複合物濃縮物

第7章重症加護治療市場：依應用分類

  • 急性冠狀動脈症候群
  • 心房顫動
  • 冠狀動脈血管成形術
  • 深層靜脈栓塞症
  • 血液透析機
  • 肺動脈栓塞
  • 外科手術

第8章美洲重症加護治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太重症加護治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲重症加護治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abeona Therapeutics Inc.
  • ADMA Biologics, Inc.
  • Albumedix Ltd. by Sartorius AG
  • Asklepios BioPharmaceutical, Inc.
  • Aspen Group
  • Bio Products Laboratory Ltd.
  • BioDelivery Sciences International, Inc.
  • Biotest AG
  • CSL Limited
  • Grifols SA
  • Kedrion Spa
  • Novartis AG
  • Octapharma AG
  • Shanghai RAAS
  • Takeda Pharmaceutical Co. Ltd.
Product Code: MRR-4311CE1A33EE

The Critical Care Therapeutics Market was valued at USD 4.77 billion in 2023, expected to reach USD 5.03 billion in 2024, and is projected to grow at a CAGR of 5.39%, to USD 6.90 billion by 2030.

Critical care therapeutics encompasses a broad array of medical solutions focused on treating life-threatening conditions requiring intensive monitoring and support, such as severe infections, organ failures, and critical post-operative states. The necessity for such therapeutics arises from the growing prevalence of chronic diseases, an aging population, and the increasing incidence of critical health situations necessitating specialized care. Applications span across various healthcare settings, including hospitals and dedicated intensive care units (ICUs), with end-use encompassing both adult and pediatric care. Key growth influencers in the market involve advancements in biotechnology and pharmaceuticals, which have led to the development of targeted therapies and personalized medicine solutions. Additionally, digital health technologies, such as AI-driven diagnostics and tele-intensive care units, present promising opportunities for market expansion. Medical professionals and healthcare facilities could leverage these technologies to enhance patient outcomes and operational efficiencies. However, the market faces limitations due to high treatment costs, stringent regulatory requirements, and potential side effects associated with advanced therapeutics. Furthermore, the COVID-19 pandemic exposed vulnerabilities in healthcare infrastructure, challenging the adaptability and resource allocation of critical care services. To capitalize on growth opportunities, stakeholders should focus on innovation in biosimilars and monoclonal antibodies, which promise more cost-effective treatments. Additionally, investment in wearable health monitoring technologies and integration of big data analytics can offer insights into patient management and optimized care pathways. The market is inherently dynamic and competitive, necessitating continuous innovation and adaptation to the evolving healthcare landscape. Companies should prioritize collaborative research initiatives and enhance cross-sector partnerships to drive growth. Emphasizing education and training for healthcare professionals on the latest therapeutics and technologies can further facilitate successful market penetration and sustainability in the domain of critical care therapeutics.

KEY MARKET STATISTICS
Base Year [2023] USD 4.77 billion
Estimated Year [2024] USD 5.03 billion
Forecast Year [2030] USD 6.90 billion
CAGR (%) 5.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Critical Care Therapeutics Market

The Critical Care Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising geriatric population worldwide and increase in prevalence of chronic diseases
    • Adoption of digitization trends and illness due to sedentary lifestyle
    • Large investments in the healthcare sector for modern medical treatments facilities
  • Market Restraints
    • High cost of therapeutics
  • Market Opportunities
    • Government activities and support for implementing critical care diagnostics
    • Rising remote communications between diagnostics and laboratories
  • Market Challenges
    • Lack of skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the Critical Care Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Critical Care Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Critical Care Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Critical Care Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Critical Care Therapeutics Market

A detailed market share analysis in the Critical Care Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Critical Care Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Critical Care Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Critical Care Therapeutics Market

A strategic analysis of the Critical Care Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Critical Care Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., ADMA Biologics, Inc., Albumedix Ltd. by Sartorius AG, Asklepios BioPharmaceutical, Inc., Aspen Group, Bio Products Laboratory Ltd., BioDelivery Sciences International, Inc., Biotest AG, CSL Limited, Grifols SA, Kedrion Spa, Novartis AG, Octapharma AG, Shanghai RAAS, and Takeda Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Critical Care Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Albumin, Antithrombin Concentrates, Factor XIII Concentrates, Fibrinogen Concentrates, and Prothrombin Complex Concentrates.
  • Based on Application, market is studied across Acute Coronary Syndrome, Atrial Fibrillation, Coronary Angioplasty, Deep Vein Thrombosis, Hemodialysis, Pulmonary Embolism, and Surgeries.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population worldwide and increase in prevalence of chronic diseases
      • 5.1.1.2. Adoption of digitization trends and illness due to sedentary lifestyle
      • 5.1.1.3. Large investments in the healthcare sector for modern medical treatments facilities
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Government activities and support for implementing critical care diagnostics
      • 5.1.3.2. Rising remote communications between diagnostics and laboratories
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of skilled professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Critical Care Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Albumin
  • 6.3. Antithrombin Concentrates
  • 6.4. Factor XIII Concentrates
  • 6.5. Fibrinogen Concentrates
  • 6.6. Prothrombin Complex Concentrates

7. Critical Care Therapeutics Market, by Application

  • 7.1. Introduction
  • 7.2. Acute Coronary Syndrome
  • 7.3. Atrial Fibrillation
  • 7.4. Coronary Angioplasty
  • 7.5. Deep Vein Thrombosis
  • 7.6. Hemodialysis
  • 7.7. Pulmonary Embolism
  • 7.8. Surgeries

8. Americas Critical Care Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Critical Care Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Critical Care Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. ADMA Biologics, Inc.
  • 3. Albumedix Ltd. by Sartorius AG
  • 4. Asklepios BioPharmaceutical, Inc.
  • 5. Aspen Group
  • 6. Bio Products Laboratory Ltd.
  • 7. BioDelivery Sciences International, Inc.
  • 8. Biotest AG
  • 9. CSL Limited
  • 10. Grifols SA
  • 11. Kedrion Spa
  • 12. Novartis AG
  • 13. Octapharma AG
  • 14. Shanghai RAAS
  • 15. Takeda Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. CRITICAL CARE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. CRITICAL CARE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CRITICAL CARE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CRITICAL CARE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CRITICAL CARE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CRITICAL CARE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTITHROMBIN CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY FACTOR XIII CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY FIBRINOGEN CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CORONARY ANGIOPLASTY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SURGERIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. EGYPT CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. EGYPT CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. FINLAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. FINLAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. FRANCE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. FRANCE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. GERMANY CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. GERMANY CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ISRAEL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. ISRAEL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ITALY CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. ITALY CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. NETHERLANDS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. NETHERLANDS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. NIGERIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. NIGERIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. NORWAY CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. NORWAY CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. POLAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. POLAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. QATAR CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. QATAR CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. RUSSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. RUSSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SAUDI ARABIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. SAUDI ARABIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SPAIN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. SPAIN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SWEDEN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. SWEDEN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SWITZERLAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. SWITZERLAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. TURKEY CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. TURKEY CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED ARAB EMIRATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED ARAB EMIRATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED KINGDOM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED KINGDOM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. CRITICAL CARE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 108. CRITICAL CARE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023